Biotech & Pharma

Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson's Apathy

34 sec read2 views0 listens

Palomar Labs has spun out Ariadne Bio, a new company focused on developing a non-hallucinogenic therapy for apathy in Parkinson's disease patients. This is significant because apathy is a debilitating symptom with limited treatment options, and Ariadne’s lead candidate, AB-300, leverages a previously studied molecule with a unique mechanism of action targeting serotonin receptors. The company is now preparing for a Phase Ib clinical trial and is backed by funding from Palomar Labs and The Michael J. Fox Foundation, with results expected to be released in Q4.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & Pharma21 hours ago34 sec read

Lilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

Eli Lilly has presented early clinical data for its experimental GIP/GLP-1 receptor agonist, brenipatide, which demonstrates a favorable safety profile and supports once-weekly dosing for potential use in substance use, psychiatric, and immunological...

Ali Nemati

AI & Machine Learning1 day ago30 sec read

I quit being a trial lawyer to become a comedian. I loved my job but knew I was ready for something different.

Paul Farahvar, formerly a trial lawyer who even won a case before the Illinois Supreme Court, has transitioned to a full-time stand-up comedian after encouragement from Bob Saget. This shift highlights a growing trend of professionals seeking new cha...

Ali Nemati

Entertainment1 day ago34 sec read

Nick Reiner says money from grandfather Carl Reiner should be available for his defense

Nick Reiner, who is awaiting trial for the murders of his parents, Rob and Michele Reiner, has filed legal documents requesting access to funds from a trust. His legal team is arguing that a portion of the $1.6 million trust, inherited from his grand...

Ali Nemati